Narrative Review: A Comparative Analysis Of The Effectiveness Of Insulin And OAD Treatment in BPJS Outpatients Patients With Type 2 Diabetes Mellitus Various Hospitals In Indonesia

Wina Oktaviana; Sri Wahyuningsih

doi:10.35451/x7rzrg82

Authors

Wina Oktaviana Universitas Jenderal Achmad Yani Cimahi Bandung
Sri Wahyuningsih Universitas Jenderal Achmad Yani, Cimahi

DOI:

https://doi.org/10.35451/x7rzrg82

Keywords:

Diabetes Mellitus Type 2, Insulin, Oral Antidiabetic Drugs, BPJS, Cost-Effectiveness

Abstract

Type 2 Diabetes Mellitus (T2DM) is a chronic disease characterized by elevated random blood glucose ≥200 mg/dL or fasting blood glucose ≥126 mg/dL, resulting from defects in insulin secretion, insulin action, or both. Type 2 Diabetes Mellitus constitutes a global health threat with a projection of 28.57 million cases in Indonesia, predicted to become a significant financial burden on the National Health Insurance System by 2045 with costs ranging from 1.6 Trillion to 3 Trillion Rupiah. This study analyzes the comparative effectiveness of Insulin versus Oral Antidiabetic Drug treatment patterns in BPJS outpatients through systematic literature review using PRISMA protocol through a primary article search on Google Scholar for the 2020-2025 period resulting in 309 articles, 299 articles did not meet the criteria for inclusive inclusion, and the remaining 10 articles continued to the assessment analysis stage. Findings reveal therapeutic equivalence of both modalities with non-significant Hba1c reduction difference (0.123%; P=0.608), yet Oral Antidiabetic Drugs demonstrate economic superiority with Metformin-Sulfonylurea combination being more Cost-Effective than Metformin-Insulin (P<0.001). Patient characteristics, comorbidities, and adherence significantly influenced therapeutic response, with 79% of patients demonstrating suboptimal glycemic control. Effectiveness variability was determined by institutional clinical protocols, and the INA-CBG rate of new-generation insulin achieved a profit margin of 3.30%. The Study provides empirical evidence for optimizing stepwise therapy algorithms prioritizing Oral Antidiabetic Drugs before Insulin Escalation within Indonesia's Health Coverage Context.

Downloads

Download data is not yet available.

References

[1] Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022;183:1–23.

[2] Soeatmadji DW, Rosandi R, Saraswati MR, Sibarani RP, Tarigan WO. Clinicodemographic Profile and Outcomes of Type 2 Diabetes Mellitus in the Indonesian Cohort of DISCOVER: A 3-Year Prospective Cohort Study. J ASEAN Fed Endocr Soc. 2023;38(1):68–74.

[3] Muharram FR, Swannjo JB, Melbiarta RR, Martini S. Trends of diabetes and pre-diabetes in Indonesia 2013–2023: a serial analysis of national health surveys. BMJ Open. 2025;15(9):1–11.

[4] Yusmaniar, Kurniawan AH, Surahman, Fauzan MN. Treatment Pattern and Cost-Effectiveness Analysis of Oral Hypoglycemics for Type 2 Diabetes Mellitus Outpatients At Regional General Hospital, Indonesia. Malaysian J Public Heal Med. 2022;22(2):27–34.

[5] Nugraha EC, Pujiyanto P, Permanasari VY. Utilisation of Hospital Outpatient Services by Diabetes Mellitus Sufferers, Analysis of BPJS Kesehatan Sample Data. Jaminan Kesehatan Nasional. 2024;4(2):144–59.

[6] Gamble J, Simpson SH, Brown LC, Johnson JA. Insulin versus an oral antidiabetic agent as add-on therapy in type 2 diabetes after failure of an oral antidiabetic regimen: a meta-analysis. Open Me. 2008;2(2):26-38.

[7] Lee YM, Lin PR, Sia HK. Oral antidiabetic therapy vs early insulinization on glycemic control in newly diagnosed type 2 diabetes patients: a retrospective matched cohort study. 2024;14(1):1-9.

[8] Wardhani KA, Artini KS, Wardani TS. Analisis Minimal Biaya Pasien Diabetes Melitus Tipe 2 di Instalasi Rawat Jalan RSUD dr. Moewardi Surakarta Periode Januari-Maret 2023.120:12–7.

[9] Lukitasari N, Waluyo DA. Analisis Efektivitas Biaya Terapi Kombinasi Pada Pasien Rawat Jalan Dengan Diabetes Melitus Tipe 2 Di RSU Swasta Jakarta Selatan. Jurnal Kesehatan Tambusai. 2024;5:4617–26.

[10] Octa MM, Putriana L, Silvyana AE, Chairunnisa DF. Analisis Biaya INA-CBG Terapi Kombinasi Insulin Pada Pasien BPJS Rawat Jalan Penderita Diabetes Melitus Tipe 2 Di RS Bhakti Kartini. J Farm Higea 2025;17(2).

[11] Ulfa NM, Fandinata S, Puspitasari I. Cost Effectiveness Analysis of Treatment of Type 2 Diabetes Mellitus Patients on Blood Glucose Control. Junal Kefarmasian Indonesia. 2023;13(1):83–94.

[12] Ulhaq DD, Indrawijaya YYA, Suryadinata A. Analisis Efektivitas Biaya Terapi Kombinasi Insulin dengan Obat Antidiabetes Oral. J Islam Pharm. 2022;7(2):112–8.

[13] Tandah MR, Diana K, Hidayat C, Ambianti N. Comparative Effectiveness of Antidiabetic Therapies on Clinical Outcomes in Type 2 Diabetes Mellitus Outpatients. J Heal Nutr Res. 2025;4(2):756–67.

[14] Fitriyani F, Andrajati R, Trisna Y. Analisis Efektivitas-Biaya Terapi Kombinasi Metformin-Insulin dan Metformin-Sulfonilurea pada Pasien Rawat Jalan dengan Diabetes Melitus Tipe 2 di RSUPN Dr. Cipto Mangunkusumo. Indones J Clin Pharm. 2021;10(1):10.

[15] Artini KS, Listyani TA. Analisis efektivitas biaya dan terapi terhadap kualitas hidup pasien diabetes mellitus type 2 rawat jalan di Rumah Sakit X, Jawa Tengah Cost-. Pharm J Islam Pharm Anal. 2024;8(1):38–49.

[16] Anggraini LF, Fitria N, Sari YO. Pengaruh Penggunaan Kombinasi Metformin-Insulin Glargine dan Metformin-Glimepiride terhadap Kadar Gula Darah Sewaktu dan Total Biaya Medis Langsung pada Pasien DM Tipe 2 di Instalasi Rawat Jalan RSUD Rupit. J Farm Higea. 2023;15(1):46.

[17] Nurul Esa Jannah, Aziz Ismunandar, Luthfi Hidayat Maulana.Analisis Efektivitas Biaya Penggunaan Antidiabetik Oral Pada Pasien Diabetes Melitus Tipe 2 Rawat Jalan Peserta BPJS Di RSUD Bumiayu 2020 .Pharmacy Peradaban Journal.2021;1(2).

[18] S. Aminah, Nur Ulina M, Br Turnip,dan Mahliza. Evaluasi Pelayanan Informasi Obat Pada Pasien Diabetes Melitus Di Rawat Jalan Instalasi Farmasi Rumah Sakit Umum Daerah Batu Bara. Jurnal Farmasimed (JFM). 2023; 5(2):213-217.

[19] Rahayu YS, Ratih A, Nurhaliza T. Evaluasi Penggunaan Antidiabetes pasien DM Tipe 2 di Puskesmas Sei Kepayang Barat Kabupaten Asahane.Jurnal Farmasimed (JFM). 2021; 5(1) :87-91.

[20] Brety LS, Romauli ATM, Dewi K. Efektivitas Kerasionalan Pemberian Antidiabetik Pengobatan Oral Pasien Diabetes Melitus Tipe 2 Pada Usia 30-50 Tahun Di Rawat Inap Penyakit dalam RSUD Deli Serdang Lubuk Pakam Tahun 2020. Jurnal Farmasimed (JFM). 2021; 3(2) :74-80.

[21] Kartini, Dedi H., Tyas SN. Analisis Efektivitas Biaya Terapi Kombinasi Antidiabetik Oral pada Diabetes Melitus Tipe 2 : Studi di RS PKU Muhammadiyah Palangka Raya. Borneo Pharmaceutical Sciences and Research. 2025;1(2) : 28-32.

[22] Faza FR, Novia M, Hajar S, Ilmiyatul M, Azian FS. Analisis Efektivitas Biaya Penggunaan Antidiabetik Oral pada Pasien Diabetes Melitus Rawat Jalan di RSU Haji Surabaya. Pharmaceutical Journal of Indonesia. 2022; 8(1): 49-58.

[23] Udayani NNW & Putu MDA. Analisis Efektivitas Biaya Penggunaan Terapi Insulin Kombinasi dan Insulin Tunggal pada Pasien Diabetes Melitus Tipe 2. Jurnal Ilmiah Indonesia. 2022; 2 (1) : 108-116.